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Edited by Masayuki MiyasakaAbstract Apolipoprotein B mRNA-editing enzyme catalytic
subunit 2 (APOBEC2) is a member of the nucleic-acid-editing
enzymes. However, the physiological function of APOBEC2 re-
mains unclear. We demonstrate that APOBEC2 expression is
strongly enhanced in response to both tumour necrosis factor-a
(TNF-a) and interleukin-1b. Inhibition of NF-jB activation
invariably blocks TNF-a-induced APOBEC2 expression. The
promoter region of APOBEC2 contains functional NF-jB re-
sponse elements in the 5 0 untranslated region of the gene at
625/616. These results show that APOBEC2 expression is
regulated by pro-inﬂammatory cytokines via NF-jB activation
and suggest a possible role of APOBEC2 in the pathophysiology
of hepatic inﬂammation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Pro-inﬂammatory cytokine1. Introduction
Nucleic acid editing modiﬁes genes and their transcripts in
many organisms, contributing to an expansion of the number
of gene products without the generation of new genes [1–3].
Recently, the apolipoprotein B mRNA-editing enzyme cata-
lytic subunit (APOBEC) family members have been shown
to be pivotal in the editing of various genes in humans. The
APOBEC family contains a group of cytidine deaminases that
include APOBEC-1, -2, -3A, -3B, -3C, -3D, -3F, and -3G, and
an activation-induced cytidine deaminase (AID) [1]. The best-
characterized example of editing performed by an APOBEC
family member is the editing by APOBEC1 of the mRNA
encoding apolipoprotein B [4–7]. APOBEC3G plays critical
roles in the cellular anti-retroviral defence mechanism [8–11].
The putative DNA-editing enzyme AID, expressed in activated
B cells in germinal centres, is essential for the somatic hyper-Abbreviations: APOBEC, apolipoprotein B mRNA-editing enzyme
catalytic subunit; AID, activation-induced cytidine deaminase; TNF-a,
tumour necrosis factor-a; IL-1b, interleukin-1b; NF-jB, nuclear fact-
or-jB; IKK, IjB kinase; NEMO, NF-jB essential modulator; HCC,
hepatocellular carcinoma; rRNA, ribosomal RNA; NRE, NF-jB
response element
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ulin genes [12,13]. In contrast to these data, little is known
about either the speciﬁc substrates or the physiological func-
tions of APOBEC2 [14].
Previous reports have shown that, like other APOBEC fam-
ily enzymes, human APOBEC2 has a deaminase activity on
cytidine and deoxycytidine in vitro [14,15]. A critically impor-
tant function of APOBEC2 might be expected because APO-
BEC2 is the most ancient DNA/RNA-editing enzyme
known. The enzyme is highly conserved throughout the verte-
brate lineage, whereas the APOBEC1 and APOBEC3 sub-
groups are restricted to mammals [14,16,17]. Although the
expression of APOBEC2 was originally thought to be re-
stricted and speciﬁcally upregulated in the heart and skeletal
muscle, a more recent analysis using a cDNA panel derived
from multiple tissues has suggested that APOBEC2 (also
termed ARCD1) transcripts are ubiquitous in both human
and mouse tissues, including the liver [14,15]. To approach
the question of the normal and possibly pathological roles of
liver APOBEC2 proteins, we investigated the expression and
regulation of human APOBEC2 in human hepatocytes.2. Materials and methods
2.1. Cell culture and transfection
The human hepatoma cell lines HepG2, Hep3B, and Huh7 were cul-
tured in Dulbecco’s modiﬁed Eagle’s medium (Gibco-BRL, Tokyo, Ja-
pan) [18]. For plasmid transfections, we used the TransIT transfection
reagent (Mirus Bio Corporation, Madison, WI). The nuclear factor-jB
(NF-jB) inhibitors SN50 and MG132 were purchased from BIOMOL
International LP (Plymouth Meeting, PA). Tumour necrosis factor-a
(TNF-a) was from PeproTech EC Ltd. (London, UK), and interleu-
kin-1b (IL-1b) from R&D Systems Inc. (Minneapolis, MN).
Normal liver tissue was obtained from the non-cancerous tissues of
patients with metastatic liver cancer at the time of surgery. Primary hu-
man hepatocytes were isolated and cultured according to a previously
described protocol [19]. Brieﬂy, the liver specimens were infused
through vascular cut ends with warmed (37 C) Hanks’ solution con-
taining 0.5 mM EDTA (Sigma, St. Louis, MO) and 1 M HEPES
(Wako Pure Chemical Industries, Osaka, Japan) using a syringe. The
tissue samples were then subjected to enzyme digestion with 0.05% col-
lagenase (Wako). The cell suspension was passed through double lay-
ers of sterile cotton gauze and ﬁltered through a single 75 lm mesh
layer of nylon cloth. The cells were then centrifuged at 50 · g for
2 min to collect the mature hepatocytes. The hepatocytes were then
suspended at a density of 5 · 105 cells/mL in Dulbecco’s modiﬁed Ea-
gle’s medium supplemented with 10% foetal bovine serum. The cells
were seeded for 24 h to allow their attachment to the dishes, and were
then further treated with human TNF-a. Total RNA was extracted





























































































































Fig. 1. Eﬀects of TNF-a stimulation on the expression of APOBEC
family genes in human hepatoma cell lines. The expression of the
APOBEC family in the absence or presence of TNF-a was analysed by
quantitative RT-PCR using lysates from Hep3B (A), HepG2 (B), or
Huh7 cells (C). Total RNA was isolated from cells 12 h after treatment
with TNF-a (100 ng/mL). Relative mRNA levels were measured by a
quantitative RT-PCR method with the oligonucleotide primers shown
in Supplementary Table 1. The data are the means ± S.D. values of
three independent experiments.
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Total RNA was isolated using the Sepasol RNA-I (Nacalai Tesque,
Kyoto, Japan) [20]. APOBEC2 expression was quantiﬁed by real-time
PCR using TaqMan Universal PCR Master Mix (PE Applied Biosys-
tems). The oligonucleotide primers and the 6-carboxyﬂuorescein
(FAM)-labelled probe used to quantify APOBEC2 ampliﬁcation were
5 0-CCAGGCTGCTCTGAAGAAGC-30 (forward), 5 0-AGGCCTTG-
GATTCACCCTCT-3 0 (reverse), and 5 0-TGCGCATCATGAA-
GCCCCAGGA-3 0 (probe). Eight human APOBEC family transcripts
were quantitatively ampliﬁed using the Platinum SYBR Green qPCR
SuperMix UDG (Invitrogen) with the oligonucleotide primers shown
in Supplemental Table 1.
To quantify isolated RNA and to measure cDNA synthesis eﬃ-
ciency, target cDNAs were normalized to the expression levels of the
endogenous reference housekeeping gene, 18S ribosomal RNA
(rRNA). The oligonucleotide primers and FAM-labelled probe used
for 18S rRNA ampliﬁcation and detection were 5 0-TAG-
AGTGTTCAAAGCAGGCCC-3 0 (forward), 5 0-CCAACAAATA-
GAACCGCGGT-3 0 (reverse), and 5 0-CGCCTGGATA-
CCGCAGCTAGGAATAATG-3 0 (probe). For simplicity, the expres-
sion levels of the target genes were expressed as values relative to the
control in each experiment.
2.3. Plasmid constructs
APOBEC2 promoter fragments were generated by PCR ampliﬁca-
tion using Takara EX Taq DNA polymerase (Takara, Tokyo, Japan)
and the oligonucleotide primers shown in Supplemental Table 2. All
reporter plasmids were constructed by inserting PCR products into
pGL3-Basic (Promega, Madison, WI). Plasmids carrying dominant
negative forms of IjB kinase-a (IKK-a) or IjB kinase-b (IKK-b)
genes, pcDNA3-IKKa (K44A) and pcDNA3-IKKb (K44A), respec-
tively, have been described previously [21].
2.4. Small interfering RNA
To make small interfering RNA (siRNA) to target the IjB kinase-c/
NF-jB essential modulator (IKK-c/NEMO), the SMARTpool kit was
obtained from Dharmacon Research (Lafayette, CO). siRNA was
transfected into HepG2 cells using TransIT-TKO siRNA Transfection
Reagent (Mirus Bio Corporation). At 36 h after transfection, the cells
were lysed for immunoblotting or were subjected to treatment with
TNF-a.
2.5. Immunoblotting analysis and promoter assay
Sample preparation and immunoblotting analysis have been de-
scribed previously [20]. Antibodies directed against IKK-c/NEMO
and a-tubulin were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). To measure the promoter activity of the 5 0 region of APO-
BEC2, luciferase reporter constructs or a promoterless pGL3-Basic
vector were individually co-transfected with pRL-TK (the internal
control plasmid; Promega) into HepG2 cells. After incubation with
TNF-a for 24 h, luciferase activities were measured using the Dual-
Luciferase Reporter Assay System (Promega) [18].3. Results
3.1. APOBEC2 expression is induced by pro-inﬂammatory
cytokine stimulation
To begin, the transcripts of eight APOBEC family genes
were quantiﬁed in human hepatoma-derived cells. The pro-
inﬂammatory cytokine TNF-a plays a central role in hepatic
inﬂammation, including viral induced hepatitis and alcoholic
liver damage [18,22,23]. Therefore, we examined the eﬀects
of TNF-a on the expression of APOBEC family genes in hepa-
tocytes. Although the transcripts of all eight APOBEC family
genes examined were detectable in Hep3B cells, only APO-
BEC2 expression was markedly elevated after TNF-a treat-
ment (Fig. 1A). Similar ﬁndings were obtained using the
human hepatoma-derived cell lines HepG2 and Huh7. TNF-
a stimulation resulted in 6-, 12-, and 8-fold increases in APO-BEC2 expression in Hep3B, HepG2, and Huh7 cells, respec-
tively (Fig. 1B and C). These ﬁndings suggest that the pro-
inﬂammatory cytokine TNF-a speciﬁcally induces human
APOBEC2 transcription in hepatocytes.
To investigate the TNF-a-mediated induction of APOBEC2
expression more precisely, we examined the time course of this
expression by incubating HepG2 cells with TNF-a. APOBEC2
mRNA was promptly induced, and the peak level was ob-
served 18 h after TNF-a treatment (Fig. 2A). Moreover,
TNF-a increased the amount of APOBEC2 transcript in a
dose-dependent manner, when measured 12 h after the begin-
ning of stimulation, whereas the expression of the internal con-
trol 18S rRNA gene was constant under all conditions tested
(Fig. 2B). To conﬁrm the TNF-a-mediated induction of APO-
BEC2 expression in human hepatocytes, we established cul-
tured primary human hepatocytes and investigated whether











































































































Fig. 2. Dose- and time-dependent eﬀects of TNF-a and time-depen-
dent eﬀects of IL-1b on the expression of APOBEC2. HepG2 cells were
incubated with the indicated concentrations of TNF-a for 12 h (B), or
with 12.5 ng/mL TNF-a (A) or 5 ng/mL IL-1b (D) for the indicated
times. (C) Changes in APOBEC2 expression after treatment with
TNF-a (12.5 ng/mL) in cultured primary human hepatocytes. In each
experiment, total RNA was isolated after cytokine stimulation, and
real-time PCR was performed using FAM-labelled probes speciﬁc for
human APOBEC2. The results were normalized to 18S rRNA
expression. The data are the means ± S.D. values of three independent
experiments.
Fig. 3. Eﬀects of inhibition of the NF-jB signalling pathways on
APOBEC2 expression. (A) SN50 (50 lg/mL) or MG132 (2 lg/mL) was
added to HepG2 cells 1 h before stimulation with TNF-a (12.5 ng/mL).
Total RNA was isolated from cells 12 h after incubation with TNF-a,
and expression levels of APOBEC2 were measured by real-time PCR.
(B) pcDNA3-IKKa (K44A), pcDNA3–IKKb (K44A), or control
vector was transfected into HepG2 cells. Cells were treated with TNF-
a 24 h after plasmid transfection. The normalized expression levels of
APOBEC2 were determined by quantitative real-time PCR. (C)
HepG2 cells were transfected with siRNA targeting IKK-c/NEMO
or control RNA, and 24 h after transfection the cell lysates were
analysed by western blotting probed with anti-IKK-c/NEMO anti-
body (upper panel) or anti-a-tubulin antibody (lower). (D) After
treatment with IKK-c/NEMO siRNA or control RNA for 24 h,
HepG2 cells were treated with TNF-a (100 ng/mL) for an additional
12 h, and the APOBEC2 expression level in each extract was quantiﬁed
by real-time PCR. CTR, control.
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regulation of APOBEC2 transcripts in primary hepatocytes
12 h after treatment with TNF-a (Fig. 2C).
Next, we examined the eﬀects of another pro-inﬂammatory
cytokine, IL-1b, on APOBEC2 expression levels. Quantitative
analysis revealed that APOBEC2 transcripts increased 18 h
after IL-1b stimulation (Fig. 2D).
3.2. Human APOBEC2 expression is regulated by NF-jB
Both TNF-a and IL-1b activate the transcription factor NF-
jB and contribute to the expression regulation of various
genes. Our ﬁnding that these cytokines induce APOBEC2 tran-
scription prompted us to test whether APOBEC2 expression is
mediated by an NF-jB-dependent mechanism. As expected,
pre-treatment with SN50 or MG132, inhibitors of NF-jB acti-
vation, almost completely suppressed the TNF-a-induced in-
crease in APOBEC2 mRNA (Fig. 3A). Activation of the
classical NF-jB pathway converges on the IjB kinase signal-
some, a protein complex composed of two kinase subunits(IKK-a and IKK-b) and a non-catalytic subunit (IKK-c/
NEMO) [24]. TNF-a-induced APOBEC2 expression was al-
most completely abolished by co-production of the dominant
negative form of IKK-a or IKK-b (Fig. 3B).
To clarify further the involvement of NF-jB in APOBEC2
expression, we used siRNA to reduce the expression of endog-
enous IKK-c/NEMO. We conﬁrmed that transfection of
IKK-c-speciﬁc siRNA, but not control siRNA, substantially
reduced endogenous IKK-c protein levels in HepG2 cells
and that the lower levels were sustained for at least three days
(Fig. 3C). Under these conditions, TNF-a stimulated the
expression of APOBEC2 in control cells. In contrast, TNF-a
failed to elicit an increase in APOBEC2 mRNA in cells in
which endogenous IKK-c was reduced by siRNA (Fig. 3D).
These ﬁndings show that the induction of APOBEC2 expres-
sion in human hepatocytes by TNF-a is achieved through
the activation of NF-jB.
Fig. 4. Characterization of the APOBEC2 promoter region. (A)
Nucleotide sequence of the 5 0 untranslated region of human APO-
BEC2. The transcription start site (NM_006789) is designated +1, and
the numbers indicate the nucleotide locations with respect to the
transcription start site. The boxes indicate the two putative NF-jB
response elements (NREs). (B) APOBEC2 promoter deletion con-
structs and analysis of the promoter region of human APOBEC2.
APOBEC2 promoter DNA sequences with various 5 0 deletions were
subcloned upstream from the luciferase reporter gene in the pGL3-
Basic vector. The reporter plasmids containing two nucleotide alter-
ations in the NREs at 625/616 (Mut-1: 5 0-CTGAGGCTCC-3 0 and
Mut-2: 5 0-GGGAGGCTAA-3 0) were also constructed. HepG2 cells
were transiently transfected with various reporter constructs. At 24 h
after transfection, the cells were treated with TNF-a (12.5 ng/mL) for
24 h. Transfection eﬃciencies were normalized to Renilla luciferase
activity, and the results are represented as relative luciferase activities
compared with those of non-treated cells. The data are the
means ± S.D. values of three independent experiments.
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confers NF-jB-dependent activation
Finally, we evaluated whether NF-jB response elements
(NREs) might be present in the DNA 5 0 to APOBEC2 (see
GenBank NM_006789). Examination of the 2000/+100 re-
gion of APOBEC2 identiﬁed two putative NREs at 625/
616 (5 0-GGGAGGCTCCT-3 0) and 81/72 (5 0-
GGGAAAGCAC-3 0), which diﬀered by one base pair and
three base pairs, respectively, from the consensus NRE (5 0-
GGGNNTYYCC-3 0) (Fig. 4A) [25]. We then examined
whether these NREs are functional in hepatocytes by con-
structing plasmids with the APOBEC2 promoter, or mutants
thereof, driving luciferase transcription. TNF-a stimulation
of HepG2 cells transfected with APOBEC2-promoter(1966/
1)–luc induced a threefold increase in luciferase activity com-
pared with that of the control cells (Fig. 4B). The highest TNF-
a-induced increase in promoter activity was observed with the
APOBEC2-promoter(930/1)–luc construct. In contrast,
plasmids lacking the putative NRE at 625/616 showed less
luciferase induction upon TNF-a treatment, whereas the con-
struct lacking the putative NRE at 81/72 showed a level of
luciferase induction similar to that of the APOBEC2-pro-
moter(1966/1)–luc construct. Moreover, the reporter activ-
ities in cells transfected with plasmids encoding an NRE
(625/616) mutated by two nucleotides were not aﬀected
by TNF-a stimulation. These ﬁndings indicate that the distal
candidate NRE (625/616) is required to activate the tran-
scription of human APOBEC2.4. Discussion
APOBEC2 is a member of the cytidine deaminase superfam-
ily that can edit RNA or DNA [14,15]. We have shown that
APOBEC2 is induced in hepatocytes by the pro-inﬂammatory
cytokines TNF-a and IL-1b through the activation of NF-jB,
whereas the transcription of the other APOBEC family genes
is not controlled by these pro-inﬂammatory cytokines. We also
found that the putative NRE at 625/616 in the 5 0 ﬂanking
region of the APOBEC2 gene functions in APOBEC2 tran-
scriptional control.
Interestingly, recent studies have shown that the aberrant
expression of molecules that edit DNA or RNA contributes
to tumourigenesis. Hepatic overexpression of APOBEC1 re-
sults in liver dysplasia and hepatocellular carcinoma (HCC)
in transgenic animals [26]. Moreover, transgenic mice that con-
tinuously express the editing enzyme AID develop malignant
T-cell lymphomas, concomitant with frequent mutations in
the T-cell receptor gene and c-myc gene [27]. These phenomena
can be explained by the abnormal editing of genes involved in
growth, diﬀerentiation, or apoptosis. It is widely recognized
that most human HCCs arise in a context of chronically in-
ﬂamed liver with the features of liver cirrhosis or chronic hep-
atitis [28–30]. Our ﬁndings that pro-inﬂammatory cytokines
induce APOBEC2 expression in hepatocytes indicate that the
induction of such genes during inﬂammation may enhance sus-
ceptibility to somatic gene alterations, in turn facilitating HCC
development. Further studies are required to identify the role
of APOBEC2 in the liver and to discover the speciﬁc substrates
of the enzyme.
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